Amgen's Repatha Shows Historic Mortality Risk Reduction in High-Risk Patients

Key Facts

1Phase 3 trial results showed Repatha reduced the risk of death in high-risk adults without a prior heart attack or stroke.

2Repatha is the first PCSK9 inhibitor shown to lower the risk of all-cause mortality in high-risk primary prevention patients.

In a move that underscores the evolving landscape of cardiovascular treatment, Amgen announced positive Phase 3 clinical trial results for its drug Repatha. According to reports, the trial demonstrated that Repatha significantly reduced the risk of death in high-risk adults who had no prior history of heart attack or stroke. Repatha is now the first PCSK9 inhibitor shown to lower the risk of all-cause mortality in high-risk primary prevention patients, addressing a critical gap in lipid management.

This breakthrough comes as clinical data highlights persistent challenges for high-risk patients who fail to reach recommended LDL-C goals through standard treatments alone. Per market data, AMGN shares closed at $436.99 on August 27, 2026, having traded between a day high of $442.13 and a day low of $431.01 during that session.

Traders are looking to see if these clinical milestones provide a long-term catalyst for the stock as it maintains its competitive edge in the biotech sector. As of the close on August 27, 2026, AMGN remains at a pivotal level; with no major sector-specific events in the immediate upcoming calendar, market sentiment is expected to be driven by the integration of this mortality data into clinical guidelines.